I am recommending the purchase of Bristol-Myers Squibb Company (NYSE: BMY) up to $63, a leading global pharmaceutical company with a large oncology presence. The stock is starting to outperform the rest of the big pharma sector which suggests that there is a possible positive surprise in the offing, perhaps within a short period of time. The company has just settled with the New York Attorney general’s office regarding off label issues with its Abilify drug for $19.5 million. This is a very inexpensive settlement and shows that management is able to make good deals. But the action in the stock suggests that there may be something bigger in the offering. I will have more in Monday’s issue of BTP Weekly.